Liver Cancer
Conditions
Brief summary
The long-term outcomes of branched-chain amino acid (BCAA) administration in patients undergoing hepatic resection remain unclear. The aim of this study is to assess the impact of oral supplementation with BCAA on the prevention for the development of liver tumorigenesis in patients undergoing liver resection.
Detailed description
This study might demonstrate a tendency of the improvement in the cumulative tumor recurrence rate after hepatectomy for liver neoplasm in the Livact group compared to that in the Control Group. The investigators believe that BCAA seems to be a remarkable benefit for liver resection, especially on its reduction in the recurrence of liver cancer. This treatment regimen has potential to offer benefits for clinical use selectively, especially for patients with chronic liver diseases.
Interventions
DRUGLIVACT
LIVACT contains 13.0 g of free amino acids
Sponsors
Kochi University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
* These patients were scheduled for elective liver resection to treat hepatocellular carcinoma or adenocarcinoma of the liver.
Exclusion criteria
* a body-weight loss greater than 10% during the 6 months prior to surgery, * the presence of distant metastases, or * serious impairment of organ function due to respiratory, renal, or heart disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative tumor recurrence rate | 5 years follow up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| nutritional status | 5 years follow up | The secondary endpoint was a comparison of measurements of body weight, arm muscle circumference (AMC) between patient groups. |
Countries
Japan
Outcome results
None listed